Over recent years there has been a growing need for patients to be sent home from hospital with prescribed opioids for ongoing management of their acute pain. Increasingly complex surgery is being performed on a day-stay or 23-hour-stay basis and inpatients after major surgery and trauma are now discharged at a much earlier stage than in the past. However, prescription of opioids to be self-administered at home is not without risk. In addition to the potential for acute adverse effects, including opioid-induced ventilatory impairment and impairment of driving skills, a review of the literature shows that opioid use continues in some patients for some years after surgery. There are also indications that over-prescription of discharge opioids occur with a significant amount not consumed, resulting in a potentially large pool of unused opioid available for later use by either the patient or others in the community. Concerns about the potential for harm arising from prescription of opioids for ongoing acute pain management after discharge are relatively recent. However, at a time when serious problems resulting from the non-medical use of opioids have reached epidemic proportions in the community, all doctors must be aware of the potential risks and be able to identify and appropriately manage patients where there might be a risk of prolonged opioid use or misuse. Anaesthetists are ideally placed to exercise stewardship over the use of opioids, so that these drugs can maintain their rightful place in the postdischarge analgesic pharmacopoeia.
Healthcare delivery is complex and fragmented, with many opportunities for failure that can adversely affect patient safety. Transition of care between hospital and home creates certain risks, particularly with lessthan-seamless continuation of medications and unclear plans for their use (whether ongoing or shortterm) after discharge. In one study, the most common post-discharge adverse events were adverse drug reactions and therapeutic errors 1 . Targeting high-risk patients and better coordination of care could prevent some of these complications and, in some cases, consequent readmission to hospital 2 .
Opioids comprise a special risk as they are among the most common cause of adverse effects in hospital practice 3 . There is also growing concern about the number of serious adverse events, including deaths, attributable to the increasing use of prescription opioids in the community, as well as the possibility of inappropriately prolonged treatment, diversion and misuse or addiction.
In Australia, more than 2.4 million hospitalisations involve surgery each year 4 and in the United States, more than 73 million surgical procedures are performed annually 5 . Over recent years there has been a growing need for many of these patients to be sent home from hospital with prescribed opioids for ongoing management of acute pain. Increasingly complex surgery is performed on a day-stay or 23-hour-stay basis and inpatients, after major surgery and trauma, are discharged much earlier than in the past. This has especially been the case with patients having operations for which there are established fast-track protocols, such as hip or knee arthroplasty 6 and colorectal 7 , gynaecological 8 , liver 9 and pancreatic 10 surgery.
Many of these patients may still have at least moderate, and at times severe, pain for several days after discharge, especially with activity. Good pain management should continue, as undertreated acute pain may compromise post-discharge rehabilitation and recovery 11, 12 . It is therefore not unreasonable for many patients to be prescribed an opioid as part of continuing multimodal management of their acute pain during transition of care from hospital to their primary healthcare provider.
Much has been written about the risks related to long-term use of opioids in patients with chronic non-cancer pain. However, there is little specific information about the risks associated with shortterm opioid management of acute pain after discharge from hospital. Published concerns about the potential problems and pitfalls in the post-discharge acute pain setting are relatively recent 12 .
This review will examine patterns of opioid prescribing for post-discharge management of acute pain and the risks that have been, or might be, associated with this practice. Such risks may include opioid-related adverse effects, unintentional initiation of long-term use, impact on driving and possible misuse and abuse of opioids resulting in potential harm to both the patient and others. It will also consider factors that should be taken into account when patients are prescribed opioids on discharge from hospital, including identification of 'at risk' patients, possible regulatory limitations to the prescribing of opioids, the choice of opioid regimen and information the patient and their treating doctors in the community may need for the coordination of care and safe management of opioid use.
DISCHARGE OPIOID PRESCRIBING IN THE ACUTE PAIN SETTING
Studies examining post-discharge opioid use following surgery show that some patients may still be taking these medications long after their pain would usually be considered acute and that the intensity and duration of pain after surgery may not be the main driver of continued opioid use. In addition, not all opioids prescribed and dispensed may be required by the patient and significant amounts of opioid may remain unused.
Unintended transition to long-term opioid use
Carroll et al 13 prospectively followed 109 patients after total hip arthroplasty, total knee arthroplasty, thoracotomy, mastectomy or lumpectomy until cessation of opioids prescribed for postoperative analgesia and cessation of pain at the operative site. For patients taking preoperative opioids, 'cessation' meant return to their preoperative opioid regimen. Opioid use and pain at the site of surgery were assessed on a daily basis. Longer duration of opioid use correlated positively with duration of postoperative pain (P=0.03), as did preoperative prescription opioid consumption (P=0.0002) and depressive symptoms (P=0.0002). Overall, 6% of patients were still taking the opioids prescribed for postoperative pain 150 days after discharge. Patients with higher levels of depressive symptoms were more likely to be still using opioids after six months. Of interest was the fact that 38% of the 21 patients taking legitimately prescribed opioids before surgery admitted to illicit opioid use compared with 7% of patients not taking prescribed opioids.
Alam et al 14 conducted a retrospective study of 391,139 opioid-naïve patients aged 66 years or older who had short-stay operations not generally considered to be associated with significant or longterm postoperative pain-cataract surgery (95% of the total number), laparoscopic cholecystectomy (2.8%), transurethral resection of the prostate (1.7%) or varicose vein stripping (0.5%). Of these, 27,636 (7%) were prescribed an opioid within seven days of their operation, including 18,231 patients after cataract surgery. The main opioids used were codeine (93.4% of patients) and oxycodone (5.4%)a mix of hydromorphone, fentanyl patches, pethidine (meperidine), morphine and slow-release (SR) oxycodone made up the remainder. More than 10% of patients prescribed an opioid after surgery were still taking an opioid one year later: they were 44% more likely to become long-term opioid users than patients who were not given a postoperative opioid prescription. Many patients had transitioned from codeine to more potent opioids over this time.
Singh and Lewallen 15 analysed information collected prospectively over a 12-year period on long-term pain and use of pain medications and their predictors in patients who had undergone primary total hip arthroplasty and were alive at the time of the two-or five-year follow-up. Data were obtained from 5707 patients at two years after surgery and 3289 patients at five years: 8.1% of patients reported moderate to severe pain and 2.3% reported continuing use of opioids at two years, with depression (but not Anaesthesia and Intensive Care, Vol. 42, No. 5, September 2014 anxiety) being significant predictors. Female gender and body mass index predicted continued opioid consumption at both two and five years. At five years, 10.8% of patients said they had moderate to severe pain and 2.8% were still using opioids.
The same group also followed up patients after primary 16 and revision total knee arthroplasty 17 over the same 12-year period. Data obtained from 7139 patients at two years and 4232 patients five years after primary total knee arthroplasty showed that female gender, patient age ≤60 years and anxiety predicted opioid use at both time periods; at two and five years 1.4% of patients were still using opioids 16 . In contrast, after revision total knee arthroplasty, continued opioid use by 5.4% of the 1533 patients at the time of the two-year follow-up and 5.9% of the 881 patients at five years correlated with patient age ≤60 years at two years and with depression at five years 17 .
These studies, while still limited in number, suggest that postsurgical discharge opioid prescribing intended for short-term management of acute pain can result in unintended initiation of longterm opioid use in some patients, and that factors predicting continued use may include depression and anxiety. At three months, persistent postsurgical pain cannot be considered acute and further evaluation is required (e.g. for evidence of a neuropathic pain component), or the patient may be using these medications to treat chronic pain from causes other than surgery or symptoms other than pain. In any case, there remains little good evidence for any benefit from long-term opioid therapy for the management of chronic pain 18, 19 .
Unused opioid
A prospective observational study by Harris et al 20 followed 212 adults after dermatological surgery involving a single skin excision. Opioids were prescribed for 72 patients (34%), an average of 8.9 tablets per patient (range of 3 to 20 tablets). The type of opioid used was not described. Of the 57 who filled their prescription, ten patients did not use any, 49 had leftover tablets and eight used all of the opioid prescribed. A total of 301 tablets were left unused, with 26 of the 49 patients planning to keep rather than dispose of them.
Another study also showed that opioids may be over-prescribed in some postoperative settings 21 .
Of the 275 out of a total of 586 patients who had undergone both major and minor urological surgery and responded to a survey, 213 had filled a prescription for a postoperative opioid.
Hydromorphone/paracetamol (acetaminophen) combinations were the most common opioid tablets prescribed (63% of patients) followed by oxycodone/ paracetamol (28%) and oxycodone alone (7%)the remainder were given tramadol or a codeine/ paracetamol combination. On average, patients were prescribed 24 tablets each: 67% of patients did not use all of them and overall, only 58% of the total number of opioid tablets obtained was consumed. Of the 164 patients who described what they had done with the surplus medication, 91% reported that they had kept them.
A study of 250 patients surveyed after outpatient upper extremity surgery 22 reported that all but five were prescribed an opioid for postoperative analgesia: hydromorphone (127 patients), oxycodone (59 patients), propoxyphene (55 patients), codeine (three patients) and the remaining patient was given propoxyphene and hydrocodone. Prescriptions were commonly for 30 tablets. A total of 77% of patients used 15 tablets or less and 4639 opioid tablets in total remained unused.
An Australian study looking specifically at discharge oxycodone prescriptions also showed that patients may be given more opioid on discharge than they need. A retrospective survey of 150 patients prescribed "as required" immediate-release (IR) oxycodone (Endone ® ) at the time of discharge after surgery reported that an average of 22 tablets was supplied 23 . Prescribed discharge doses were inconsistent with inpatient use in the 24 hours prior to discharge in 40 patients and 22 patients were prescribed oxycodone even though they had not required any opioid in the 24 hours prior to leaving hospital. In another Australian teaching hospital, the number of discharge prescriptions for Endone ® was noted to have risen three-fold over seven years 24 .
These findings show that many opioid prescriptions may not be appropriate in terms of anticipated severity or duration of postoperative pain (e.g. after cataract surgery) or type or formulation of opioid (e.g. fentanyl patches, pethidine). They also reveal a potentially very large pool of unused opioid medications in the community resulting from overprescription.
POTENTIAL ADVERSE CONSEQUENCES OF OPIOID PRESCRIBING AT DISCHARGE
Patients prescribed an opioid at the time of discharge from hospital remain at risk from potential adverse effects due to the non-analgesic effects of the medications, whether in the short or long term. Unintended long-term opioid use has been referred to above, but there may also be other risks to the patient and others if the opioid is misused or abused.
Opioids and adverse drug events
It is known that opioid-related adverse drug events are common in postoperative patients. In one study, 13.6% of those receiving opioids experienced such an event. Risk factors were age 65 years or older, male sex, obesity, preoperative opioid use and higher comorbidity scores 25 . If the patient has been in hospital and taking opioids, it is likely that any acute adverse effects (e.g. nausea and vomiting or pruritus) will have been identified before discharge. However, if the patient is taking them for the first time at home, or if following discharge the dose is not titrated well to pain intensity and adverse effects, these problems may first arise there. The adverse effect of most concern is respiratory depression, more correctly described as opioid-induced ventilatory impairment (OIVI), because it may involve excessive sedation and upper airway obstruction and not just decreased rate and depth of breathing 26 .
The frequency of OIVI in the acute pain inpatient setting is estimated to be less than 0.5% 27 , although the true incidence is not easy to determine because of different assessment methods and reporting 26 . While uncommon, its importance relates to its potential for significant morbidity or death. An analysis of 341 closed malpractice claims associated with postoperative acute pain management in inpatients between 1990 and 2009 identified 86 cases which arose from OIVI 28 . Nearly 80% of these patients died or were left with severe brain damage. Administration of non-opioid sedating medications, more than one physician prescribing medications, evidence of obstructive sleep apnoea and observed snoring were all noted to be risk factors 28 . These risks, in addition to patient fatigue (e.g. sleep deprivation) and concurrent medical conditions such as obesity and chronic obstructive pulmonary disease, have been recognised elsewhere 26 .
Concurrent use of sedatives (in particular benzodiazepines and alcohol) with opioids is known to increase the risk of deaths associated with both illicit and legally prescribed opioid use [29] [30] [31] [32] [33] [34] [35] . In a study of over 600,000 patients prescribed opioids for chronic non-malignant pain, of the 498 who died as a result of opioid toxicity, benzodiazepines were present in 60% of cases and alcohol in 18.5% 30 . These patients were significantly more likely to be using benzodiazepines, antidepressants and other central nervous system depressants and to have a history of alcohol dependence than the control patients who died of other causes while taking their long-term opioids.
There are currently no data for the risk of OIVI in patients discharged home after surgery and who will be taking opioids at home, but other sedating drugs, including alcohol, may be more readily available than in an inpatient setting. The risk may also increase with higher opioid doses, as occurs in patients taking long-term opioids, where there is a correlation between opioid dose and mortality rate 36, 30, 37 .
A less often considered adverse effect is the risk of falls. Patients treated with long-term opioids for chronic non-cancer pain are at higher risk 38, 39 , but there is also an increased risk of falls-related injury requiring hospital admission in patients newly prescribed an opioid, especially within the first week of treatment 40 . Surprisingly, this was most pronounced in young adults aged 18 to 29 years.
Other adverse effects of opioids associated with long-term use, such as immune suppression, changes in endocrine function, fractures, sleepdisordered breathing, constipation, an increased risk of cardiovascular events and opioid-induced hyperalgesia 41 will become relevant if patients remain on opioids for a prolonged period.
Impaired driving ability
There is little information about the prevalence of driving under the influence of drugs, but European data show that it may be more common than previously thought 42 . In a sample of 50,000 randomly tested drivers from 13 countries, approximately 1.9% tested positive for an illicit substance, with illicit opioids in 0.07%. Medically prescribed opioids were detected among 0.35% of the drivers 42 . An Australian study of fatally injured drivers reported that opioids were present in 4.9% 43 , while the proportion of drivers involved in fatal and non-fatal traffic accidents in eight countries in Europe and testing positive for an opioid ranged from 0.4% to 9% 44 .
The ability to perform complex tasks such as driving may be decreased by opioids, as they can lead to cognitive impairment, diminished reaction times, reflexes and coordination, and an inability to concentrate [44] [45] [46] . However, there may be differing effects between opioid-naïve patients first exposed to opioids for the management of new acute pain, those who are opioid-tolerant on long-term opioid therapy but who have had a recent adjustment made to their dose, and patients on a stable maintenance dose of opioid.
Most reports suggest that once the dose is stable, opioid drugs do not usually impair driving performance 44, 46, 47 or increase crash risk 44, 48 , although caution is recommended about generalising the conclusions of some of the studies to all patients in everyday practice 49 . However, mishap while driving may be increased in the first few weeks of being prescribed an opioid 47 . Driver risk may be opioid dose-related 50 and psychomotor function may be impaired if patients on long-term opioid therapy have acute increases in their dose 44 . It is therefore often recommended that patients be advised not to drive for up to four weeks until their opioid doses are stabilised or if they are taking variable doses of short-acting opioids 45, 48 .
The European project Driving Under the Influence of Drugs, Alcohol and Medicines in Europe (DRUID) 51 was a five-year project involving 18 countries. It provided conflicting evidence about the effect of opioids on driving. Tests of five skills considered relevant for safe driving (stress tolerance, visual orientation ability, concentration, attention and reaction speed) showed that performance in patients who had been taking opioids at stable doses for at least four weeks was significantly worse than in opioid-naïve controls, but that there was no difference between the two groups when actual driving ability was compared 52 . The effect of opioids was said to be similar to a blood alcohol reading of 0.05 to 0.08 g/100 ml and the DRUID project recommendations were that "a legal limit for patients undergoing long-term treatment is inappropriate; sanctions should be based on degree of impairment" 51 .
For patients prescribed opioids (IR or SR) for ongoing management of their acute pain after discharge from hospital, doses may vary during each day according to the pain experienced and will ideally taper as recovery occurs. Their opioid doses are therefore not stable. Should tapering not match the reduction in pain, then the effect of the opioid may become excessive. Recommendations about the advice that should be given to drivers therefore tend to err on the side of caution. It has been suggested that they be counselled about driving until they no longer need an opioid 45, 48 and that they should also be warned against concurrent use of sedatives including benzodiazepines, alcohol and cannabis 45 .
Drug interactions
Even when opioids are used as prescribed by the patients for whom they were prescribed, the risk of drug interactions is high, especially in medically complicated patients who often take multiple medications, have several physicians involved in their care and may not inform their doctors about all medications that they take 53 . Drug interactions can occur because of predictable pharmacokinetics (opioids share the metabolic pathways of many other drugs), resulting in altered toxicity or efficacy, or because of the often unappreciated synergistic effects of opioids and sedatives including benzodiazepines, some antiemetics and alcohol 54, 55, 28 . Potential drug interactions between opioids and other prescription drugs have been estimated to occur in 26% of patients with non-cancer chronic pain 56, 57 . There are no good data available relating to drug interactions and opioid use for post-discharge acute pain management.
When prescription opioids are borrowed or shared, the risk of drug interaction may be even higher 58, 59 . In Australia and the USA, one of the most commonly shared medication groups is opioids 58 . Up to 42% of Australians aged over 60 years admit to hoarding their prescription medications 58 .
Non-medical use of prescription opioids
Any reservoir of unused opioid in the home is potentially available for use by either the patient or others (including family members or visitors) for nonmedical purposes and may have significant public health consequences 60 . These opioids may be diverted, misused, abused or otherwise result in harm, not only to the patient but to others 60 , including contributing to a risk of unintentional poisoning of children 61 .
In the USA in 2010 to 2011, the most common source (54%) of prescription opioids for non-medical use was a friend or relative, 82% of whom had been prescribed them by a doctor 62 , although the main source may vary depending on the opioid 63 . In Australia, around half of those who obtained morphine and oxycodone for non-medical use sourced these drugs from friends; the rates were higher for methadone and buprenorphine-naloxone used for the treatment of opioid addiction 64 .
Often overlooked is the contribution from elderly patients who may be selling some of their prescription opioids 65 . The "activity of buying prescription drugs from elderly people for personal use or to sell illegally" is colloquially known as "fossil pharming" 66 .
Patterns of opioid misuse vary. In the USA, hydrocodone, codeine and oxycodone, including SR oxycodone, have been the most popular 67 . Lifetime use (at least once in a lifetime) of SR oxycodone for non-medical purposes in the USA trebled between 2005 and 2010 68 . In Australia in 2012, among known illicit injecting drug users interviewed about their drug use (by any route of administration including injection, swallowing and smoking) in the preceding six months, 60% admitted to heroin, followed by methadone (46%), morphine (43%) and oxycodone (39%) 64 . When asked which opioids they had injected in the prior six months, 60% had injected heroin, 40% morphine, 33% oxycodone and 22% methadone 64 . The rate of misuse of morphine in this group has remained relatively stable over time, but oxycodone abuse by any route 64 has risen significantly from 21% in 2005 69 to 39% in 2012 64 .
Prescription opioids: prescription rates, mortality and morbidity
In many parts of the world the rapid rise in the number of prescriptions for opioids has coincided with a concurrent increase in opioid-related morbidity and mortality. In the USA between 1997 and 2007, retail sales of oxycodone, hydromorphone, hydrocodone and morphine rose by 866%, 319%, 280% and 222% respectively 68 . From 1999 to 2010, the number of USA drug poisoning deaths involving any opioid analgesic (e.g. oxycodone, methadone or hydrocodone) more than quadrupled 70 , and 61% of drug poisoning deaths in women involved prescription opioids 71 . The increase was five-fold for women and 3.6 times for men and, overall, was four times the rate of cocaine and heroin deaths combined 71 . The number of emergency department visits in the USA related to prescription opioids increased by 153% between 2004 and 2011; visits involving oxycodone alone rose by 220% in the same period 72 .
In Australia, there has been a significant rise in the total number of opioid prescriptions issued under the Australian Pharmaceutical Benefits Scheme, from nearly 2.4 million in 1992 to almost 7 million in 2007 73 . Between 2002 to 2003 and 2007 to 2008 there was a 20% decrease in the number of morphine prescriptions (per 1000 population), while oxycodone prescriptions rose by 152% over the same period 55 . There has also been a doubling, between 1999 and 2007, of the number of hospital separations where the principal diagnosis was said to be poisoning with "other opioid" (this includes morphine, oxycodone and codeine) 55 . In the Australian state of Victoria, oxycodone prescriptions increased nine-fold between 2000 and 2009; in 2000 there were four coronial cases in which oxycodone was detected and by 2009 this had increased to 97 54 .
Unfortunately, the increase in morbidity and mortality related to prescription opioids also includes young children and babies, usually as a result of exposure to drugs prescribed for adults in the household 74 .
A study examining the relationship between adult use of hypoglycaemics, antihyperlipidaemics, betablockers and opioids found that increasing use was associated with rising paediatric exposures and poisonings, but the strongest association and most serious injuries and hospitalisations occurred most frequently with opioids and the risk was greatest in the month following the first prescription 61 .
IDENTIFICATION OF THE ' AT RISK' PATIENT
Caution is necessary when prescribing drugs with potentially severe adverse effects that include serious harm, such as addiction and overdose. Identification of patients who may be at risk of long-term use of opioids commenced for the management of their acute pain, as well as those patients where the possibility of diversion and/or misuse and abuse exists, are necessary if these risks are to be prevented, or at least reduced. The purpose is not necessarily to avoid the use of opioids when indicated, because every patient in pain has a right to appropriate treatment. Rather, treatment has to be organised so that the chance of these risks is minimised.
Opioid use and psychological risk factors
Once established, long-term opioids are commonly not discontinued and those on higher doses (greater than 120 mg oral morphine equivalents per day) are more likely to prolong their opioid use beyond 90 days than those on lower doses 75, 76 .
While the studies previously discussed identified depression or depressive symptoms 13, 15, 17 and anxiety 16 as predictors of prolonged opioid requirements after surgery, various psychological factors including depression and anxiety have also been linked to greater opioid use and/or higher pain scores in a number of acute and chronic pain settings.
In the early postoperative period, preoperative anxiety and depression or negative affect and pain catastrophising may correlate with higher postoperative opioid requirements and/or pain intensity [77] [78] [79] [80] [81] [82] [83] [84] . Catastrophising refers to the tendency of some individuals to ruminate about their pain, magnify or exaggerate pain and its threat value and feel helpless about their ability to do anything about it 85 .
A higher risk of persistent postsurgical pain after a variety of different operations has also been associated with several psychological factors including preoperative anxiety and pain catastrophising 86 , preoperative depression, psychological vulnerability and stress 87 . Other studies of pain associated with a variety of types of surgery confirm these findings [88] [89] [90] [91] [92] .
Similarly, after motor vehicle accidents, early reports of widespread pain in patients with musculoskeletal injuries not requiring hospital admission were associated with depressive symptoms and pain catastrophising, but not with characteristics indicating the severity of the collision (e.g. extent of motor vehicle damage, collision type) 93 . In other studies, anxiety and/or depression also played an important role in the persistence of pain after acute musculoskeletal trauma [94] [95] [96] .
Anaesthesia and Intensive Care, Vol. 42, No. 5, September 2014 The influence of psychological factors on the pattern of opioid use is also seen in a number of different chronic pain states, where it is known that mental health diagnoses such as depression, anxiety, catastrophising, post-traumatic stress disorder and personality disorders, or a history of substance abuse, are associated with initiation and prolonged use of prescribed opioids [97] [98] [99] [100] [101] [102] .
Long-term opioid use is said to be characterised by a pattern of 'adverse selection', where patients at the highest risk of adverse outcomes, such as those with a history of mental health or substance abuse disorders, are also more likely to receive high-risk opioid treatment, including high daily opioid doses, high potency opioids and concurrent sedativehypnotic medications 103 .
Diversion, misuse and abuse
Mental health diagnoses including depression, anxiety, catastrophising and borderline personality disorders have also been linked to an increased risk of opioid misuse and/or addiction [104] [105] [106] [107] . Patients with a history of substance abuse have been shown to use seven times more opioid for chronic pain than patients with no history of abuse and be four times more likely to have had a mental health diagnosis in the last 12 months. Risk of abuse was also associated with having another family member with a mental health diagnosis, substance abuse or prescription opioid use 108 .
'Chemical coping' is a term initially coined by Bruera in 1995 109 to describe maladaptive behaviour in alcoholic patients in palliative care. It has since been redefined by Kirsh and Passik to depict patients who "occasionally use their medications in non-prescribed ways to cope with stress" 110 . Most addicted patients are chemical copers, but the majority of chemical copers are probably not addicted 111 . In one study comparing patients with chronic pain and those with an opioid addiction, patients in the latter group had a higher incidence of psychiatric comorbidities and were much more likely to think that opioids would help reduce stress and make them relaxed, happier and more content 112 .
Screening tools used to identify potential opioid misuse, abuse and diversion
It should be emphasised that the purpose of screening for potential opioid misuse, abuse and diversion is not to deprive patients with acute pain of opioid treatment where indicated, but rather, to identify those at risk so they can be provided with appropriate arrangements and monitoring, aiming to reduce the risk of adverse outcomes 113 . The patient should be assessed in their social context by considering their living arrangements and obtaining collateral history from a spouse or significant other 114 .
A simple screening question of "how many times in the past year have you used an illegal drug or used a prescription medication for non-medical reasons" has been found to be highly sensitive in identifying current drug use disorders. A response of even once (or more) had a sensitivity of 100% 115 . However, when deciding whether there is a possibility of abuse of opioids prescribed at discharge, screening tools that help assess the potential risk of abuse rather than just identifying current opioid or other substance abuse may be of more value.
A number of screening tools used to predict risk of misuse before initiation of opioids are available and have been reviewed by Passik et al 116 and Chou et al 117 .
In general, these tools have been validated in chronic non-cancer pain patients in different settings, but they may be of use in the acute pain setting when a postdischarge opioid prescription is being considered. These include the Opioid Risk Tool (ORT), the Screener and Opioid Assessment for Patients with Pain (SOAPP) and the Brief Risk Interview. Other tools that can be used to assess whether patients prescribed long-term opioids for management of their chronic pain may be misusing them after therapy has been initiated have also been evaluated [116] [117] [118] .
The ORT 119 is a five-item tool designed to predict the possibility of aberrant behaviour and drug abuse in patients prescribed opioids for chronic pain. It stratifies patients into low (unlikely to abuse opioids), moderate or high risk (likely to abuse opioids) groups by looking at gender, family history and personal history of alcohol, illegal drug or prescription drug misuse, age, history of pre-adolescent sexual abuse and psychological conditions (with depression distinguished from other psychological disorders). More than 90% of patients stratified into the highrisk group are likely to display opioid-related aberrant behaviours 119 . One potential problem with the ORT is that, because it relies on self-reporting, it can be open to deception and manipulation of results 114, 116 . An ORT completed by a psychologist was a better predictor of aberrant drug-taking behaviour 120 .
SOAPP is a more detailed self-report questionnaire designed to assess patients with chronic pain prior to commencing opioid therapy. It was found to be more sensitive than the ORT in predicting aberrant drugtaking behaviour in a group of patients discharged from opioid therapy due to drug misuse 121 , while a focused clinical interview with a psychologist had the highest sensitivity for prediction of aberrant behaviour.
The Brief Risk Interview was developed following recognition that a detailed psychological assessment more accurately predicts aberrant behaviour than self-report tools 122 . It comprises a structured interview assessing 12 categories and requires the clinician to rate the responses from six varying risk levels. It was found to more frequently identify high-risk patients than the self-report tools of SOAPP and ORT 122 . However, such a clinical assessment requires specialist expertise and time.
SOAPP (and its variations) are more reliable at predicting aberrant drug-taking behaviours and risk of opioid abuse than the ORT, but they are more involved and take longer to administer. They may be better suited to more specialist centres and high-risk pain populations 114, 123 . The ORT, while less sensitive and more susceptible to deception, is quick and easy to administer 116 and is useful in high volume practice 123 , such as in an acute care setting. In this setting, information about drug use volunteered by the patient may be supplemented in some cases by information obtained from other sources (such as the first-responders) or blood and urine drug screens done at the time of admission. It may also be reasonable to use a broader definition of "family" when allocating scores and include, for example, the friends with whom the patient resides. In the acute pain setting, questions about pre-adolescent sexual abuse may be best omitted, as limited time is often spent with each patient.
Based on the assessment of risk, a decision can be made as to whether a discharge opioid prescription is appropriate. If opioids are to be provided to patients considered at risk, especially of prolonged opioid use, this risk should be communicated to the primary care practitioner to whom the care is transitioning, suggesting a structured dose tapering program optimising the use of non-opioid and nondrug treatment modalities, and close monitoring of the patient. Patients at higher risk, especially at risk of opioid misuse or diversion, may require referral to a pain management or drug and alcohol service for post-discharge continuing care.
Universal precautions
As there is no fail-safe method to predict which patients will develop an addictive disorder when given long-term opioids for acute pain, it has been recommended that every clinician involved in prescribing opioids should adopt a cautious and standardised approach by using "universal precautions" 124 .
Universal precautions have been described as a "systematic set of procedures and tools that aid the physician in gathering relevant information, help the physician interpret the information collected and provide a pathway for responsible decisions" 125 . The procedures include: an assessment through screening for the risk of opioid abuse, selecting appropriate opioid therapy, compliance monitoring on a regular basis (not only to assess whether the treatment is effective, but also whether there are any aberrant behaviours detected), use of prescription monitoring programs where available and having a plan should treatment be ineffective or opioid abuse or misuse be detected 123, 125 .
FACTORS TO CONSIDER BEFORE DISCHARGE
Before providing opioids for management of acute pain post-discharge, there should be a thorough review of the severity of pain and current opioid requirements and whether non-opioid measures would suffice. The prescriber should also determine the earliest time when the patient can attend their primary care provider to continue management of analgesia.
Choice and formulation of opioid and duration of treatment
If opioids are prescribed at discharge, consideration should be given to both the opioid type and duration of therapy. There is no evidence for 'best choice' or 'best formulation' of opioid (IR or SR) to be used for ongoing management of acute pain after discharge, although fentanyl patches should not be prescribed and are currently contraindicated in most countries for use in patients with acute and postoperative pain. Methadone should also not be used unless the doctor who will continue with its prescription is familiar with its complex pharmacology and experienced in its use.
Points to consider are whether an activity-based regimen using an IR opioid would better suit the variations in pain that will accompany different levels of activity as the patient continues their rehabilitation, or whether a more constant level of opioid is preferred, and the ease with which downward titration or tapering can be achieved with either regimen. In patients taking opioids for long-term treatment of chronic non-cancer pain, there was a greater than two-fold increase in opioid requirements when timecontingent dosing schedules using predominantly long-acting opioids were used, compared with paincontingent dosing using predominantly short-acting formulations 126 . Therefore use of IR opioids after discharge may be appropriate.
Anaesthesia and Intensive Care, Vol. 42, No. 5, September 2014 Of the IR opioids, codeine may be contraindicated because of pharmacogenetic variations in the enzyme CYP2D6, which is responsible for the metabolism of codeine to morphine. Unpredictable, and sometimes fatal, elevations of plasma morphine levels have been reported in individuals who are carriers of CYP2D6 duplication (ultra-rapid metabolisers) 127 . Similarly, formation of O-desmethyltramadol, the main active metabolite of tramadol, is also dependent on CYP2D6. Ultra-rapid metabolisers are more sensitive to the effects of tramadol and may be at higher risk of adverse events 128 .
It may also be worth considering the street value of the opioid that is to be prescribed. In 2012, the national Australian median costs per tablet were 10 mg methadone-$20.00, 8 mg buprenorphine (used in opioid-substitution programs, both with and without naloxone)-$25.00, 100 mg SR morphine-$70.00 to $80.00, and 40 mg and 80mg SR oxycodone were $30.00 and $50.00 respectively, making a single box of the SR opioids, which contain 28 tablets each, quite valuable 64 . In comparison, heroin and cocaine were $50.00 per point and methamphetamines were $50.00 per point. A cap is defined as a "small amount, typically enough for one injection" and a point as "0.1 gram, although may also be used as a term referring to an amount for one injection" 64 .
Abuse liability (the 'attractiveness' of a substance for abuse) is another potential consideration. This is said to depend upon factors such as accessibility/ availability, cost, peer preferences and features of the drug such as speed of onset, ease of extraction and intensity and duration of effect 63, 129 . In the USA, oxycodone and hydrocodone/paracetamol combinations are the most common drugs of choice of those who abuse prescription opioids 130 . Hydrocodone is rated as 'less attractive' on the Opioid Attractiveness Scale, but it is relatively cheap and more easily accessible because of its less restrictive scheduling status 130 and has a high abuse rate 129 . Diversion, and therefore ease of access, to opioids is known to be related to the number of prescriptions written 130 and oxycodone and hydrocodone/paracetamol are the two most commonly prescribed opioids in the USA 130 .
The combination of paracetamol with all hydrocodone products in the USA may act as a deterrent to abuse, as the risks of liver damage associated with high doses of paracetamol are often well known by those who take opioids for non-medical use 130 . Unfortunately, the risks of high doses of nonsteroidal anti-inflammatory drugs appear to be less well understood, as has been seen with the significant morbidity that has been associated with abuse of over-the-counter codeine-ibuprofen combinations 131 .
Some 'tamper-resistant' formulations of opioids such as buprenorphine with naloxone (Suboxone ® ; Reckitt Benckiser Healthcare Limited, Slough, UK) and SR oxycodone with naloxone (Targin ® ; Mundipharma Pty Limited, Sydney, NSW) combine an opioid agonist with an opioid antagonist, which may reduce the risk of diversion and injection, but not necessarily abuse via other routes. Other tamperresistant formulations, which have been or are being developed, use physicochemical barriers designed to help retain the time-release mechanism if the drug is tampered with, for example by crushing or dissolving it to make it suitable for use via other, more rapidly acting, routes of administration including inhalation (snorting) and intravenous injection 63 .
The introduction in the USA of a tamper-resistant formulation of extended-release (ER) oxycodone in the third quarter of 2010 was followed by reductions in diversion rates and street price 132 and a marked decrease (from 36% to just 13%) in those surveyed at three-monthly intervals for 20 months who listed ER oxycodone as their primary prescription opioid of abuse 133 . While use of the reformulated ER oxycodone within the last 30 days (at each survey interval) also fell significantly, two-thirds of the respondents reported that they had changed to another opioidmost commonly heroin, which had a nearly doubling of use, with a smaller number opting for other oxycodone products 133 . A 66% reduction in past-30day non-oral abuse (injecting, snorting and smoking) was also reported over the 20 months following the release of the ER oxycodone 134 . Oral abuse of the drug has also declined, but a significant proportion of those misusing the reformulated ER oxycodone still continued to misuse it by the oral route 135 .
For a detailed review of the different types of abuse-deterrent opioids and the technology involved, see Moorman-Li at el 136 .
The dose and duration of opioid prescribed at discharge should also be appropriate in terms of the anticipated severity and duration of the ongoing acute pain, and patients should not be prescribed higher opioid doses than they required prior to discharge. The duration of treatment should be limited to the expected duration of pain and/or the interval before the patient's primary care practitioner can evaluate the need for ongoing analgesia, should it be required. The dose should usually be progressively reduced. The aim is to treat ongoing acute pain on a short-term basis only and not inadvertently contribute to the risk of initiating long-term opioid use. One concept that can be introduced to both health professionals and patients is the 'Reverse Pain Ladder', in which the same steps as the World Health Organization Pain Ladder are used, but in the reverse order: "strong" opioid plus non-opioid, stepping down to "weak" opioid (tramadol may be an appropriate choice) plus non-opioid, and finally to non-opioids alone 137 .
Failure to taper the opioid should trigger a reassessment of analgesic need by the primary care practitioner, e.g. looking for evidence of a neuropathic pain component and management, as for a patient with chronic pain. Once patients receive opioids for longer than 90 days, there is an increased risk that their opioid use may be prolonged or even lifelong 75, 76 .
Repeat prescriptions for an opioid should be given only after careful assessment of the patient and factors (physical, psychological and social) that might be contributing to their pain, as well as optimisation of the full range of non-opioid multimodal pain treatments. Some patients may be using opioids to treat chronic pain from causes other than the surgery or injury for which they were first prescribed, or using them to cope with stress, anxiety and depression 76 . Patients with factors suggesting that they might be at risk of prolonged opioid use may benefit from a physician-guided tapering of opioid doses, rather than being left to reduce their own doses over time 13 . Interval dispensing of opioids for self-administration at short intervals (even on a daily or second-daily pickup basis) may also be appropriate in some patients.
Regulatory limitations to the prescription of opioids
In Australia, the different states and territories have enacted legislation that places some controls on the prescription of opioid medications (as controlled drugs or drugs of dependence) to patients in the community and all prescribers must be aware of the relevant regulations that apply in their area of practice. Links to sites containing the relevant legislation in Australia and New Zealand are listed in Table 1 .
In general, although there are some exemptions (e.g. in palliative patients or patients older than 70 years), prescription of opioids to non-drug dependent patients for more than two months is not permitted unless some form of permit or authorisation is obtained. In New South Wales the restrictions are limited to any injectable form of any drug of addiction, buprenorphine (except transdermal preparations), hydromorphone and methadone. There are no similar limitations in New Zealand. These state and territory permit requirements in Australia are separate to the authority that may be required for a patient prescribed a subsidised medicine.
However, in both countries, prescription of an opioid to patients suspected or known to be dependent on a controlled drug (i.e. addicted to a controlled drug) is prohibited without authorisation.
This means that if a patient is taking opioids on a long-term basis before admission to hospital, changes to the dose of that drug or the addition of any extra opioid (if thought appropriate) when the patient is discharged will usually require prior discussion with the patient's prescribing doctor. Even if not required by legislation, such discussion would seem prudent.
Tramadol prescription does not have the same regulatory limits, including for those patients with an addiction. However, tapentadol has been classed as a Schedule 8 (controlled drug or drug of dependence) in Australia.
Communication with the patient's primary care practitioner
There is potential for harm during the transition of care from the hospital to the patient's primary care practitioner. Improved communication and coordination of care could prevent some of the adverse Table 1 Links to relevant legislation and other information outcomes that have been reported 2 . The patient's pain management plan at discharge and advice, if needed, about tapering strategies, should be communicated to their treating doctor. In the discharge letter, details of the opioid prescription should clearly stand out from other discharge medications. Some hospital electronic systems have "long-term" as the default duration of therapy when medications details are entered into the letter to be sent to the primary care practitioner. It is important that is changed to a short-term option for any opioids prescribed at discharge. Written advice with suggestions for an estimated duration of therapy and dose reduction strategies is best, although this will vary according to the individual patient and the reason for their acute pain.
Patient information
Patients need to have enough information and advice to enable them to safely use any opioids prescribed for them when they leave hospital (see Table 2 ). They should be aware that expected duration of opioid therapy will be short and that further opioid prescriptions will depend on an assessment by their doctor, so that any expectation of longer-term use is dispelled at an early stage. The patient may also perceive that the hospital has greater authority in deciding these matters than their own doctor, so this advice should mitigate this expectation.
Patients should also be advised that their ability to perform complex tasks may be impaired by opioids and that they should not drive, operate machinery, ride a bike or make important personal or business decisions while taking these medications. Just as level of sedation is used to detect the onset of OIVI in hospital 26 , the patients, their associates and their family need to be given information about the significance of increasing or excessive sedation and whether they should just reduce the dose or seek urgent assistance. As it is known that the risk of OIVI is increased with the concurrent use of sedatives, the patient should avoid drinking alcohol or taking sedative medications such as benzodiazepines. They should also know to store their opioids out of the reach of others and not give any of their tablets to other people. Written information should be supplemented with verbal information where possible. One example of a printed patient information sheet can be found on the South Australia Health website 138 . Patients are given this information sheet as well as a verbal explanation by a clinical pharmacist when they leave the hospital.
Education of current and future doctors
As the supply of opioids and the problems they cause continue to increase, there is a need for medical practitioners to be better informed about these potential risks and the potential for harm. This should start with the education of those who will be doing the prescribing-from medical school onwards.
However, not all medical schools provide such education. In a survey of Canadian universities, all the veterinary programs allocated significantly more time to pain education than other disciplines, including medicine, nursing and pharmacy 139 . Veterinary and physiotherapy undergraduate programs in the United Kingdom also allocated more time to pain in their teaching than the programs for medicine, nursing, dentistry and pharmacy 140 . Similarly, at one university in the USA, the number of hours devoted to pain education was higher in the dentistry and physician assistant schools than the schools of medicine, nursing, pharmacy and social work 141 . Opioid prescribing was covered in only 30% of medical schools in the USA and abuse and addiction in only 10% 142 . Recent recommendations for topics to be incorporated into medical student pain curricula include responsible prescribing of opioids and prescribing skills, drug addiction and pain management and recognition and management of aberrant drug behaviours [142] [143] [144] .
After a survey showing that only 21% and 15% of medical students felt that they had received enough pain-related didactic and clinical education respect- Table 2 Essential information for patients prescribed an opioid on discharge from hospital While taking opioids for continuing pain after discharge patients and their carers should be advised:
• Not to take more medication than prescribed and to take a little less each day
• Not to give their medication to anyone else • To store their medication in a safe place and out of reach of others ively, the University of Washington in the USA implemented a four-year integrated pain curriculum aimed to increase both which, it is hoped, will better equip the students for medical practice 145 . An increase from 6 to 25 hours of pain-specific course content has been achieved and includes information on drug misuse and abuse. At the University of Adelaide some teaching about pain is done in the early undergraduate years (didactic but case-centred), but the main teaching is done in the fifth and sixth years. In their fifth year, every student does a "Pain Week" as part of their three-week anaesthesia, pain medicine and intensive care attachment, where they learn about acute and chronic pain and pain in palliative care using a mix of case and problem-based learning, didactic talks, and clinical experience. Learning in their sixth year, still under the umbrella of the Department of Anaesthesia and Pain Medicine, aims to equip them better for practice as an intern.
In this, their final year, the acute pain sessions cover practical prescribing for inpatients and those being discharged from hospital, as well as management of acute nociceptive and neuropathic pain in different patient populations, including those on long-term opioid medications and/or those with an addiction disorder. Importantly, they learn they are welcome at any time to seek advice. Intern sessions on acute pain management and appropriate prescribing are held at the start of each year as well as throughout the year, conducted by anaesthetists from the Acute Pain Service and clinical pharmacists from the Pharmacy Department of the hospital.
CONCLUSIONS
The rapidly growing problem of misuse, abuse and diversion of prescription opioids is wellrecognised but, until recently, has been considered mainly in the context of opioids prescribed for the management of chronic pain. Responsible opioid prescribing is as important in acute pain medicine as it is in chronic pain medicine and needs to involve consideration of the right regimen for the right patient at the right time in the right context with the right tapering of doses accompanied by a proper risk assessment of each patient before prescription. Passik et al 116 said, in reference to opioid prescribing for chronic non-cancer pain, "it is clear that the standard of care is fast becoming one in which some form of risk stratification of patients being considered for some form of opioid therapy must be carried out and documented". This advice applies equally to opioids prescribed for acute pain management.
The importance of assessing psychosocial factors in patients with chronic pain has long been recognised. While there will be considerable limitations on time in busy hospital and acute pain settings, factors such as depression, anxiety and other mental health disorders such as post-traumatic stress disorder and catastrophising, must be taken into account in patients with acute pain, as these may impact on opioid prescribing both while in hospital and upon discharge. This is not to suggest that patients with psychological disorders should not be discharged home with opioids if thought appropriate. However, better identification of patients at risk of inadvertent longterm opioid use may assist in deciding which patients may benefit from closer follow-up after discharge.
Similarly, there should be an assessment made of the risks of opioid abuse and diversion in any patient started on opioids for management of their acute pain, especially in those being discharged from hospital and who may require continuing management of their pain. Where the risk of diversion or misuse is assessed as being high or the patient is known or thought to be addicted to a controlled drug, closer follow-up may be required and limitations placed on the availability of opioids by prescription.
Better assessment and management of the potential risks associated with post-discharge opioid prescribing in the acute pain setting may benefit from input by, and training of, anaesthetists. Many anaesthetists may not agree they should be involved, but noninvolvement, at least to some degree, is not really an option. Most anaesthetists will have prescribed analgesia for patients after day surgery, for example, or at least been consulted about such prescriptions. Others will prescribe postoperative opioid analgesia for inpatients after surgery and those in acute pain services will prescribe opioids to follow patientcontrolled and epidural analgesia. It is not enough to believe that the responsibility of the anaesthetist stops there. Anaesthetists are exemplars of best opioid analgesia use and students and junior medical staff may not question their example. Anaesthetists commonly do not have to consider 'exit strategies' for the drugs they start, as most drugs will start and stop in the operating room or the post-anaesthesia recovery unit, but this is not the case in acute pain medicine. If an opioid is started by an anaesthetist, an anaesthetist needs to contribute to planning for appropriate tapering and discharge regimens rather than leaving it to others with less knowledge and experience.
One solution for better post-discharge opioid prescribing might be to ensure that patients who have been under the care of an acute pain service continue to be seen by someone from that acute pain service while they require an opioid so that a discharge plan can be formulated 24 . However, this means that only a small proportion of patients might be seen before they leave hospital. It may therefore be better to educate all junior staff in ways to improve the safety of discharge plans involving opioids. Guidance for junior staff on a one-to-one basis may not always be possible, but anaesthetists, ideally in collaboration with pharmacy colleagues, can help develop hospital and state-wide guidelines which provide relevant information and suggestions 146 .
Since the problems associated with the increasing use of opioids have escalated, it is no longer sufficient for anaesthetists to confine their attention to pain relief following a particular procedure or injury in hospital. The acute pain management regimen chosen must be tailored for the individual patient (whether in hospital or the patient's home), taking into account not only any medical comorbidities they may have, but also any relevant psychosocial and risk factors.
Steyaert and Lavand'homme 12 stressed the need for anaesthetists to be mindful of the potential risks of discharge opioid prescriptions saying, "…we must be aware of what happens to our patients when they leave hospital because, in the end, we are responsible for the consequences of the opioids we prescribe". The questions that will be asked by some will be "Why anaesthetists?" and/or "Why my department?". The answer is not simply "Why not?" but "Who better?". McCoy 147 stated that "there is a responsibility that future generations of anaesthetists are educated in the management of pain in all its forms", which would include pain after a patient leaves hospital. It is anaesthetists who must be responsible for leading the changes that are required and the education of future generations of students and trainees. In order to acquire the appropriate knowledge and skills, all anaesthetists must be given the proper education, training and experience in pain medicine in general and acute pain medicine specifically. This is especially important for anaesthetists who will work without the readily available backup of acute or chronic pain services.
Serious problems involving opioid analgesics have reached epidemic proportions and are described as a public health crisis in North America 148, 149 . Anaesthetists are ideally placed to exercise stewardship over use of opioids, so that these potentially dangerous drugs can maintain their rightful place in the analgesic pharmacopoeia.
